|Bid||617.58 x 1300|
|Ask||618.06 x 1400|
|Day's range||614.55 - 627.46|
|52-week range||271.37 - 664.64|
|Beta (5Y monthly)||0.55|
|PE ratio (TTM)||23.93|
|Earnings date||03 Nov 2020 - 09 Nov 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||672.04|
Regeneron (REGN) beats on Q2 earnings and sales on solid performance of Dupixent and oncology drug, Libtayo.
Regeneron (REGN) delivered earnings and revenue surprises of 14.93% and 9.05%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
The National Institutes of Health is starting a head-to-head trial of several antibody treatment candidates.